Rubius Therapeutics, Inc. - RUBY STOCK NEWS

Rubius Therapeutics (Nasdaq: RUBY) announced it will present preclinical data on RTX-224 at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting from November 10-14, 2021. RTX-224 aims to enhance immune responses against tumors by utilizing 4-1BB ligand and interleukin-12. The data suggests RTX-224 activates immune cells in the spleen and blood, potentially increasing their presence in tumor areas. The company plans to submit an Investigational New Drug application to the FDA by year-end, indicating progress in their development pipeline.

Rubius Therapeutics (Nasdaq: RUBY) announced its executive management team's participation in key healthcare investment conferences, including the Morgan Stanley 19th Annual Global Healthcare Conference from September 9-13, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 14, 2021.

CEO Pablo J. Cagnoni will present a corporate update during a fireside chat at the Morgan Stanley event on September 10 at 9:30 a.m. EDT, with a live audio webcast available. Rubius is focused on developing Red Cell Therapeutics™ for cancer and autoimmune diseases.

Rubius Therapeutics, Inc. (Nasdaq: RUBY) has appointed Jim Jogerst as chief business officer, effective immediately. With over 20 years of experience in mergers and acquisitions valued over $20 billion, Jogerst will lead business development and partnerships to enhance Rubius’ pipeline of Red Cell Therapeutics™ for treating cancer and autoimmune diseases. Previously, he held significant roles at Janssen Pharmaceuticals and Alcon, Inc. His appointment is expected to strengthen the company's strategic direction and expand its reach in the healthcare market.

Rubius Therapeutics (RUBY) announced the dosing of the first patient in a Phase 1/2 trial of RTX-240 combined with KEYTRUDA® for advanced solid tumors. The company has added cohorts in the RTX-240 single-agent trial due to initial positive results and no reported dose-limiting toxicities. For Q2 2021, Rubius reported a net loss of $50.2 million ($0.56 per share), an increase from $37.9 million ($0.47 per share) in Q2 2020. The cash position stood at $298.2 million as of June 30, 2021, boosted by a public offering. Future clinical data is expected by early 2022.

Rubius Therapeutics (Nasdaq: RUBY) announced the appointment of Dannielle Appelhans as chief operating officer, effective August 9, 2021. With extensive experience in corporate strategy and technical operations, she is set to enhance the company’s growth in developing Red Cell Therapeutics™ for cancer and autoimmune diseases. Previously, Appelhans held senior roles at Novartis, managing late-stage development and manufacturing. Her leadership is expected to drive efficiency and patient outreach as Rubius aims to scale operations and expand its therapeutic footprint globally.

Rubius Therapeutics (Nasdaq: RUBY) has announced its plan to report second quarter financial results on August 9, 2021, prior to market opening. The company is focused on developing Red Cell Therapeutics™, a new class of cellular medicines for cancer and autoimmune diseases. Rubius uses its proprietary RED PLATFORM® for engineering red blood cells. Notably, the company will not hold a teleconference accompanying the results announcement. Rubius has been recognized as a top workplace in Massachusetts and Rhode Island in 2020 and 2021 respectively.

Rubius Therapeutics (Nasdaq:RUBY) announced promising preclinical data for its lead oncology program, RTX-240, published in Cancer Immunology, Immunotherapy. The findings illustrate RTX-240’s ability to activate and expand CD8+ T cells and NK cells, showcasing significant anti-tumor activity in colorectal and melanoma models. Compared to a 4-1BB agonist antibody, RTX-240 exhibited improved safety and a wider therapeutic window. The ongoing Phase 1/2 clinical trial is designed to evaluate its safety, tolerability, and anti-tumor efficacy in patients with advanced solid tumors and acute myeloid leukemia.

Rubius Therapeutics (Nasdaq:RUBY) has initiated dosing of the first patient in a new Phase 1 arm of its ongoing Phase 1/2 clinical trial for RTX-240, in combination with KEYTRUDA® (pembrolizumab), targeting relapsed or refractory solid tumors. This collaboration aims to enhance immune response against cancer. The trial will assess the safety, pharmacokinetics, and anti-tumor activity of RTX-240, which is designed to stimulate immune system cells. Initial data from the monotherapy trial indicate a promising safety profile and potential efficacy.

Rubius Therapeutics, a clinical-stage biopharmaceutical company specializing in Red Cell Therapeutics, will have its CEO, Pablo J. Cagnoni, participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 p.m. EDT. The event will be webcast live and available for 90 days afterward. Rubius focuses on genetic engineering of red blood cells for innovative therapies aimed at treating cancer and autoimmune diseases. The company has received accolades for its workplace environment, being recognized among the top places to work in Massachusetts and Rhode Island.